192 related articles for article (PubMed ID: 38280072)
41. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
Han TT; Xu LP; Liu DH; Liu KY; Zhang XH; Chen H; Chen YH; Han W; Wang FR; Wang Y; Wang JZ; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):651-4. PubMed ID: 23978013
[TBL] [Abstract][Full Text] [Related]
42. Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
Yang TT; Song XL; Zhao YM; Ye BD; Luo Y; Xiao HW; Chen Y; Fu HR; Yu J; Liu LZ; Lai XY; Ye YS; Lan JP; Huang H; Shi JM
Ann Hematol; 2022 Dec; 101(12):2731-2741. PubMed ID: 36318288
[TBL] [Abstract][Full Text] [Related]
43. Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study.
Gerbitz A; Gary R; Aigner M; Moosmann A; Kremer A; Schmid C; Hirschbuehl K; Wagner E; Hauptrock B; Teschner D; Roesler W; Spriewald B; Tischer J; Moi S; Balzer H; Schaffer S; Bausenwein J; Wagner A; Schmidt F; Brestrich J; Ullrich B; Maas S; Herold S; Strobel J; Zimmermann R; Weisbach V; Hansmann L; Lammoglia-Cobo F; Remberger M; Stelljes M; Ayuk F; Zeiser R; Mackensen A
Front Immunol; 2023; 14():1251593. PubMed ID: 37965339
[TBL] [Abstract][Full Text] [Related]
44. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation.
Gasior M; Ferreras C; de Paz R; Bueno D; Mozo Y; Sisinni L; Canizales JT; González B; Olivas-Mazón R; Marcos A; Romero AB; Constanzo A; Mirones I; Fernández-Arroyo A; Balas A; Vicario JL; Escudero A; Yuste VJ; Pérez-Martínez A
Transfusion; 2021 May; 61(5):1505-1517. PubMed ID: 33713461
[TBL] [Abstract][Full Text] [Related]
45. Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation.
Liu J; Chang YJ; Yan CH; Xu LP; Jiang ZF; Zhang XH; Liu KY; Huang XJ
J Infect; 2016 Sep; 73(3):261-70. PubMed ID: 27311748
[TBL] [Abstract][Full Text] [Related]
46. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.
Gotoh M; Yoshizawa S; Katagiri S; Suguro T; Asano M; Kitahara T; Akahane D; Okabe S; Tauchi T; Ito Y; Ohyashiki K
Transpl Infect Dis; 2014 Jun; 16(3):440-9. PubMed ID: 24810656
[TBL] [Abstract][Full Text] [Related]
47. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.
Zhou L; Gao ZY; Lu DP
Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495
[TBL] [Abstract][Full Text] [Related]
48. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.
Jiang W; Clancy LE; Avdic S; Sutrave G; Street J; Simms R; McGuire HM; Patrick E; Chan AS; McCaughan G; Myers N; Micklethwaite KP; Antonenas V; Selim AG; Ritchie D; Bateman CM; Shaw PJ; Blyth E; Gottlieb DJ
Blood Adv; 2022 Sep; 6(17):4949-4966. PubMed ID: 35819448
[TBL] [Abstract][Full Text] [Related]
49. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
50. Features of Epstein-Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen.
Ru Y; Zhu J; Song T; Ding Y; Zhu Z; Fan Y; Xu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu C; Chen S; Ma X; Chen F; Chen J; Wu D
Front Cell Infect Microbiol; 2022; 12():865170. PubMed ID: 35651756
[TBL] [Abstract][Full Text] [Related]
51. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
52. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
53. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
54. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
55. Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.
Burns DM; Tierney R; Shannon-Lowe C; Croudace J; Inman C; Abbotts B; Nagra S; Fox CP; Chaganti S; Craddock CF; Moss P; Rickinson AB; Rowe M; Bell AI
Blood; 2015 Dec; 126(25):2665-75. PubMed ID: 26450987
[TBL] [Abstract][Full Text] [Related]
56. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
57. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.
Tey SK; Kennedy GA; Cromer D; Davenport MP; Walker S; Jones LI; Crough T; Durrant ST; Morton JA; Butler JP; Misra AK; Hill GR; Khanna R
PLoS One; 2013; 8(10):e74744. PubMed ID: 24146744
[TBL] [Abstract][Full Text] [Related]
58. Impact of Early Natural Killer Cell Reconstitution on the Outcomes of T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.
Zhou Z; Liu X; Zhang X; Wen S; Hua H; Wang Z; Xu Z; Lu Y; Wang F
J Inflamm Res; 2023; 16():2993-3008. PubMed ID: 37489148
[TBL] [Abstract][Full Text] [Related]
59. Incidence, risk factors, and clinical significance of Epstein-Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation.
Wang H; Zhang TT; Qi JQ; Chu TT; Miao M; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
Ann Hematol; 2019 Apr; 98(4):987-996. PubMed ID: 30715567
[TBL] [Abstract][Full Text] [Related]
60. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
Liu J; Kong J; Chang YJ; Chen H; Chen YH; Han W; Wang Y; Yan CH; Wang JZ; Wang FR; Chen Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Clin Microbiol Infect; 2015 Dec; 21(12):1121.e9-15. PubMed ID: 26093077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
